Market Cap 2.44B
Revenue (ttm) 2.20B
Net Income (ttm) -713.41M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE 7.75
Profit Margin -32.45%
Debt to Equity Ratio 0.73
Volume 3,157,600
Avg Vol 3,006,998
Day's Range N/A - N/A
Shares Out 104.99M
Stochastic %K 91%
Beta 0.29
Analysts Sell
Price Target $21.65

Company Profile

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, siRNA platform, gene therapy, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of Duchenne in patients who have a confirmed mutation of the dyst...

Industry: Biotechnology
Sector: Healthcare
Phone: 617 274 4000
Address:
215 First Street, Suite 415, Cambridge, United States
hegdaom
hegdaom Apr. 5 at 5:28 AM
0 · Reply
WBinthehouse
WBinthehouse Apr. 5 at 2:36 AM
$SRPT lol you’re the biggest loser. You’ve been here pumping the stock then lost all your money now bashing it. I got a life. I made money not you BIG LOSER.
0 · Reply
WBinthehouse
WBinthehouse Apr. 5 at 2:31 AM
$SRPT The DMD mother of a patient in the video is right! A confirmatory trial ENVISION, also called SRP-9001-303 was already ongoing at that time. Nonambulatory patients, ages 4 plus with confirmed DMD mutation received accelerated approval based on micro dystrophin expression as a surrogate endpoint reasonably likely to predict clinical benefit. The FDA noted limited safety data for non ambulatory patients at approval with safety primarily extrapolated from ambulatory data. ENVISION a global Phase 3 randomized, double blind, placebo controlled trial in older ambulatory and non-ambulatory DMD patients, was already underway and designated as the post marketing confirmatory study for the non ambulatory indication. Non amb was shelved due to safety reasons. Elevidys doesn’t work significantly for ambulants kids what makes you think it will work for non ambs who have lost muscle function already. Jut a waste of money that’s why the FDA is not bringing it back even with sirolimus.
0 · Reply
biomaster22
biomaster22 Apr. 5 at 1:08 AM
$SRPT what a moron this WB is, who brags about posting on a stock board for 10 years get a life, what a loser.
1 · Reply
WBinthehouse
WBinthehouse Apr. 4 at 6:18 PM
$SRPT @Atmwireless yah clearly the poster doesn’t know SRPTs product so I try to correct the falsehood. I’ve been on SRPTs board for over 10 years so that formed my knowledge on what is truly going on. Folks think Im bashing the stock, that’s not true, I get a charge when they go off the rails that shows how misinformed and frustrated they truly are. The mother in the video accusing SRPT of just taking money for Doug’s snake oil during the 2024 PPMD annual convention, that cannot be debunked. The truth hurts literally and figuratively. The stock took a dump. Up to this day all PMOs have exceeded their time in confirmatory collecting billions without proving anything significantly in return. Vinay Prasad will approve a DMD drug that’s RCT battled, met regulatory rigor, didn’t kill anybody just to prove a point that surrogate endpoints are not enough in approving rare and orphan drugs. If not Vinny someone else lol. $CAPR
2 · Reply
neilcaornish
neilcaornish Apr. 4 at 12:03 PM
$SRPT Post-market gave back a small portion, nothing unusual after a run like that. Watching how it holds overnight.
1 · Reply
Retter7
Retter7 Apr. 4 at 12:44 AM
$AAPL $MSFT The conflict in the Middle East is rapidly escalating, which could impact market sentiment on Monday. Just as conditions in the market were beginning to improve, Iran reportedly shot down two U.S. jets, potentially shifting momentum in its favor. Developments like this typically lead to a negative market response. A possible path forward would involve pressuring Iran to halt its nuclear weapons development, end its support for regional militias, and accept limits on its missile program. Otherwise, market sentiment may continue trending downward rather than upward. However, in the case of $SRPT, its stock volatility and performance have been driven more by internal company issues rather than direct impacts from war-related supply chain disruptions.
1 · Reply
Martinsucks
Martinsucks Apr. 3 at 11:53 PM
$SRPT just when things were going great. 2 u.s jets shot down. Monday will be a slaugherhouse
1 · Reply
DragonAlgo
DragonAlgo Apr. 3 at 8:28 PM
🐉 $SRPT CALL — DragonAlgo® Signal Contract: SRPT CALL Expiry: 2026-04-17 | Strike: $17.50 | Type: CALL Option Plan (premium): Entry: $5.60 Stop: $4.03 TP1: $7.28 TP2: $9.52 TP3: $13.44 🔗 https://dragonalgo.com
0 · Reply
KY3000
KY3000 Apr. 3 at 7:04 PM
$SRPT I hope RFK next
0 · Reply
Latest News on SRPT
Why Is Sarepta Therapeutics Stock Exploding Today?

Mar 25, 2026, 11:17 AM EDT - 10 days ago

Why Is Sarepta Therapeutics Stock Exploding Today?


Sarepta CEO To Jump Ship After 'Tumultuous' Year

Feb 26, 2026, 5:52 AM EST - 5 weeks ago

Sarepta CEO To Jump Ship After 'Tumultuous' Year


Sarepta Therapeutics CEO Ingram to retire by year end

Feb 26, 2026, 5:05 AM EST - 5 weeks ago

Sarepta Therapeutics CEO Ingram to retire by year end


Sarepta Therapeutics: Is Elevidys A Bust?

Jan 16, 2026, 9:25 AM EST - 2 months ago

Sarepta Therapeutics: Is Elevidys A Bust?


Sarepta Shares Jump After FDA Approves Updated Elevidys Label

Nov 14, 2025, 5:48 PM EST - 5 months ago

Sarepta Shares Jump After FDA Approves Updated Elevidys Label


Sarepta Stock Dumps: Pharma Bro Martin Shkreli Still Likes It

Nov 4, 2025, 12:11 PM EST - 5 months ago

Sarepta Stock Dumps: Pharma Bro Martin Shkreli Still Likes It


Sarepta's Duchenne gene therapy misses main goal in study

Nov 3, 2025, 4:24 PM EST - 5 months ago

Sarepta's Duchenne gene therapy misses main goal in study


hegdaom
hegdaom Apr. 5 at 5:28 AM
0 · Reply
WBinthehouse
WBinthehouse Apr. 5 at 2:36 AM
$SRPT lol you’re the biggest loser. You’ve been here pumping the stock then lost all your money now bashing it. I got a life. I made money not you BIG LOSER.
0 · Reply
WBinthehouse
WBinthehouse Apr. 5 at 2:31 AM
$SRPT The DMD mother of a patient in the video is right! A confirmatory trial ENVISION, also called SRP-9001-303 was already ongoing at that time. Nonambulatory patients, ages 4 plus with confirmed DMD mutation received accelerated approval based on micro dystrophin expression as a surrogate endpoint reasonably likely to predict clinical benefit. The FDA noted limited safety data for non ambulatory patients at approval with safety primarily extrapolated from ambulatory data. ENVISION a global Phase 3 randomized, double blind, placebo controlled trial in older ambulatory and non-ambulatory DMD patients, was already underway and designated as the post marketing confirmatory study for the non ambulatory indication. Non amb was shelved due to safety reasons. Elevidys doesn’t work significantly for ambulants kids what makes you think it will work for non ambs who have lost muscle function already. Jut a waste of money that’s why the FDA is not bringing it back even with sirolimus.
0 · Reply
biomaster22
biomaster22 Apr. 5 at 1:08 AM
$SRPT what a moron this WB is, who brags about posting on a stock board for 10 years get a life, what a loser.
1 · Reply
WBinthehouse
WBinthehouse Apr. 4 at 6:18 PM
$SRPT @Atmwireless yah clearly the poster doesn’t know SRPTs product so I try to correct the falsehood. I’ve been on SRPTs board for over 10 years so that formed my knowledge on what is truly going on. Folks think Im bashing the stock, that’s not true, I get a charge when they go off the rails that shows how misinformed and frustrated they truly are. The mother in the video accusing SRPT of just taking money for Doug’s snake oil during the 2024 PPMD annual convention, that cannot be debunked. The truth hurts literally and figuratively. The stock took a dump. Up to this day all PMOs have exceeded their time in confirmatory collecting billions without proving anything significantly in return. Vinay Prasad will approve a DMD drug that’s RCT battled, met regulatory rigor, didn’t kill anybody just to prove a point that surrogate endpoints are not enough in approving rare and orphan drugs. If not Vinny someone else lol. $CAPR
2 · Reply
neilcaornish
neilcaornish Apr. 4 at 12:03 PM
$SRPT Post-market gave back a small portion, nothing unusual after a run like that. Watching how it holds overnight.
1 · Reply
Retter7
Retter7 Apr. 4 at 12:44 AM
$AAPL $MSFT The conflict in the Middle East is rapidly escalating, which could impact market sentiment on Monday. Just as conditions in the market were beginning to improve, Iran reportedly shot down two U.S. jets, potentially shifting momentum in its favor. Developments like this typically lead to a negative market response. A possible path forward would involve pressuring Iran to halt its nuclear weapons development, end its support for regional militias, and accept limits on its missile program. Otherwise, market sentiment may continue trending downward rather than upward. However, in the case of $SRPT, its stock volatility and performance have been driven more by internal company issues rather than direct impacts from war-related supply chain disruptions.
1 · Reply
Martinsucks
Martinsucks Apr. 3 at 11:53 PM
$SRPT just when things were going great. 2 u.s jets shot down. Monday will be a slaugherhouse
1 · Reply
DragonAlgo
DragonAlgo Apr. 3 at 8:28 PM
🐉 $SRPT CALL — DragonAlgo® Signal Contract: SRPT CALL Expiry: 2026-04-17 | Strike: $17.50 | Type: CALL Option Plan (premium): Entry: $5.60 Stop: $4.03 TP1: $7.28 TP2: $9.52 TP3: $13.44 🔗 https://dragonalgo.com
0 · Reply
KY3000
KY3000 Apr. 3 at 7:04 PM
$SRPT I hope RFK next
0 · Reply
WBinthehouse
WBinthehouse Apr. 3 at 3:55 PM
$SRPT @JohnyGoGoGo . I will have the last laugh I promise. I wouldn’t celebrate just yet. Careful on siRNA development. Yep there is one death in the SRP-1003 DM1 trial. According to Sarepta’s March 25, 2026, clinical data update and supporting coverage, there was one fatal serious adverse event (SAE) due to cardiac arrhythmia in the SRP-1003-101 Phase 1/2 trial for DM1. It occurred in Cohort 1 (lowest dose) several weeks after a single low dose. DM1 itself carries a known high risk of cardiac issues, including conduction abnormalities, bradyarrhythmias, and ventricular tachycardia. This aligns with the disease’s natural history cardiac problems are a leading cause of morbidity/mortality in DM1. You’ve been warned. The SAE is real. Anyone throwing money on this ticker might as well bet black or white in Vegas.
2 · Reply
adamdickense
adamdickense Apr. 3 at 2:14 PM
$SRPT that midday breakout and hold is exactly what a stock looks like when the thesis is finally getting repriced 👀 pipeline is doing the talking
0 · Reply
jtiy88
jtiy88 Apr. 3 at 11:44 AM
$SRPT the chart is doing chart things. the pipeline is doing pipeline things. one of those actually matters for where this goes. Up all the way I suppose
0 · Reply
Andysss
Andysss Apr. 3 at 7:31 AM
$SRPT Remember CFO only gets paid if the stock massively rerates ($67$155 strikes). If the incentive structure is clearly skewed toward a multi-bagger outcome. Then I join with my money. Worth thinking about regardless of your position…
0 · Reply
DragonAlgo
DragonAlgo Apr. 3 at 5:24 AM
🐉 $SRPT CALL — DragonAlgo® Signal Contract: SRPT CALL Expiry: 2026-04-17 | Strike: $17.50 | Type: CALL Option Plan (premium): Entry: $5.60 Stop: $4.03 TP1: $7.28 TP2: $9.52 TP3: $13.44 🔗 https://dragonalgo.com
0 · Reply
Jimxsmith
Jimxsmith Apr. 3 at 3:31 AM
$SRPT Rare Disease Leaders Call for Regulatory Clarity as FDA Balances Urgency With Rigor https://www.biospace.com/fda/rare-disease-leaders-call-for-regulatory-clarity-as-fda-balances-urgency-with-rigor
0 · Reply
UptownMichelle
UptownMichelle Apr. 3 at 3:00 AM
$SRPT The FDA’s Treatment of Rare Disease Patients Is a National Disgrace https://pjmedia.com/melissa-ortiz/2026/03/30/the-fdas-treatment-of-rare-disease-patients-is-a-national-disgrace-n4951258#google_vignette
0 · Reply
StarlinePalaceTrades
StarlinePalaceTrades Apr. 3 at 2:10 AM
If you're looking to get in to these small float runners early before the breakouts... @ElevenXProfits is a good trader Follow, banked on many of his picks. 💎💯 Top watch next week: $IXHL $SRPT $NWBO $AVCTQ
0 · Reply
Newbilly
Newbilly Apr. 3 at 1:43 AM
$SRPT April & May belong to us
1 · Reply
SagaSeeker
SagaSeeker Apr. 3 at 1:15 AM
$SRPT 25-30$ price target
0 · Reply
WBinthehouse
WBinthehouse Apr. 2 at 11:54 PM
$SRPT @johnnygogogo lol you can’t debunk this video. That’s why the price is the price. Your hate post is weak compared to all the haters that came at me at $175 going down. This fucking stock is one death away going to zero. You know the new RNA theraphy had one death already. Though it’s being denied and not mention it can happen again. Go ahead make fun of my post. A lot of your kind ain’t laughing anymore. lol
3 · Reply
Martinsucks
Martinsucks Apr. 2 at 11:42 PM
$SRPT it's up almost 50% in a month and people still talking shit ( I blocked them ) but fan see the reposts.
0 · Reply